Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. read more

EMPLOYEE PARTICIPANTS: 80

TOTAL RATINGS: 549

CEO: Reshma Kewalramani

HR or Marketing? Claim Your Free Employer Account

Reshma Kewalramani Vertex Pharmaceuticals CEO Rating

Vertex Pharmaceuticals' CEO, Reshma Kewalramani, has 55 employee ratings and a score of 82/100, placing them in the Top 5% of similar size companies on Comparably with 1,001-5,000 Employees and Top 10% of other companies in Boston. When breaking the CEO score down by factors such as department, gender, and ethnicity, we see that females at Vertex Pharmaceuticals rate Reshma Kewalramani higher than males, giving the CEO a score of 93/100.

Last updated months ago.

Where This Score Ranks Vertex Pharmaceuticals' CEO Rating

TOP
5%
In the Top 5% of 2126 Similar Sized Companies on Comparably
TOP
10%
In the Top 10% of 270 Nearby Companies in Boston
1st
1st place versus 3 competitors rated on Comparably

Dec

Jun

Sep

Dec

Feb

A+82 / 100

Jan

Vertex Pharmaceuticals CEO Reshma Kewalramani Bio

Reshma Kewalramani serves as the CEO / President of Vertex Pharmaceuticals.

Who Ranks Vertex Pharmaceuticals' CEO Rating the Highest?

Department - HR 100/100

Department - Finance 97/100

Ethnicity - Caucasian 94/100

Who Ranks Vertex Pharmaceuticals' CEO Rating the Lowest?

Experience - 3 to 6 Years 68/100

Ethnicity - Asian or Pacific Islander 70/100

Gender - Male 72/100

Vertex Pharmaceuticals CEO Reshma Kewalramani At a Glance

The CEO score provides an understanding of how employees feel about the CEO’s leadership style and effectiveness at Vertex Pharmaceuticals.

Based on 55 ratings, Reshma Kewalramani ranks right above Biogen's CEO, Michel Vounatsos.

Vertex Pharmaceuticals' CEO is highly regarded by the HR department, the Finance department, and Caucasian employees. However, employees with 3 to 6 Years experience, Asian or Pacific Islander employees, and Male employees have a less favorable view of the CEO and believe there is room for improvement. Overall, the CEO score has remained stable over the last 90 days.